Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan E Henriksen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Diabetes Technology & Therapeutics|February 24, 2007
AKA-TPG: a program for kinetic and epidemiological analysis of data from labeled glucose investigations using the two-pool model and database technologyRaymond C Boston, Darko Stefanovski, Jan E Henriksen, et al.
Journal of Hypertension|October 11, 2013
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trialChristina S Oxlund, Jan E Henriksen, Lise Tarnow, et al.
Plos One|May 12, 2018
Critical-depth Raman spectroscopy enables home-use non-invasive glucose monitoringSigne M Lundsgaard-Nielsen, Anders Pors, Stefan O Banke, et al.
Public Health Nutrition|November 11, 2014
Missing portion sizes in FFQ--alternatives to use of standard portionsRasmus Køster-Rasmussen, Volkert Siersma, Thorhallur I Halldorsson, et al.
Diabetes Care|October 19, 2013
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetesVibe Skov, Claudia Cangemi, Jeppe Gram, et al.
Diabetes & Vascular Disease Research|August 7, 2014
Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patientsDana Bar-Shalom, Mikael K Poulsen, Lars M Rasmussen, et al.
Diabetes Care|January 29, 2021
A Validated Prediction Model for End-Stage Kidney Disease in Type 1 DiabetesDorte Vistisen, Gregers S Andersen, Adam Hulman, et al.
Cardiovascular Diabetology|August 16, 2011
Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitusMikael K Poulsen, Mads Nybo, Jordi Dahl, et al.
ACS Sensors|March 6, 2023
Accurate Post-Calibration Predictions for Noninvasive Glucose Measurements in People Using Confocal Raman SpectroscopyAnders Pors, Kaspar G Rasmussen, Rune Inglev, et al.
Diabetes/Metabolism Research and Reviews|April 27, 2018
Pathophysiology-based phenotyping in type 2 diabetes: A clinical classification toolJacob V Stidsen, Jan E Henriksen, Michael H Olsen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Diabetes Technology & Therapeutics|February 24, 2007
AKA-TPG: a program for kinetic and epidemiological analysis of data from labeled glucose investigations using the two-pool model and database technologyRaymond C Boston, Darko Stefanovski, Jan E Henriksen, et al.
Journal of Hypertension|October 11, 2013
Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trialChristina S Oxlund, Jan E Henriksen, Lise Tarnow, et al.
Plos One|May 12, 2018
Critical-depth Raman spectroscopy enables home-use non-invasive glucose monitoringSigne M Lundsgaard-Nielsen, Anders Pors, Stefan O Banke, et al.
Public Health Nutrition|November 11, 2014
Missing portion sizes in FFQ--alternatives to use of standard portionsRasmus Køster-Rasmussen, Volkert Siersma, Thorhallur I Halldorsson, et al.
Diabetes Care|October 19, 2013
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetesVibe Skov, Claudia Cangemi, Jeppe Gram, et al.
Diabetes & Vascular Disease Research|August 7, 2014
Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patientsDana Bar-Shalom, Mikael K Poulsen, Lars M Rasmussen, et al.
Diabetes Care|January 29, 2021
A Validated Prediction Model for End-Stage Kidney Disease in Type 1 DiabetesDorte Vistisen, Gregers S Andersen, Adam Hulman, et al.
Cardiovascular Diabetology|August 16, 2011
Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitusMikael K Poulsen, Mads Nybo, Jordi Dahl, et al.
ACS Sensors|March 6, 2023
Accurate Post-Calibration Predictions for Noninvasive Glucose Measurements in People Using Confocal Raman SpectroscopyAnders Pors, Kaspar G Rasmussen, Rune Inglev, et al.
Diabetes/Metabolism Research and Reviews|April 27, 2018
Pathophysiology-based phenotyping in type 2 diabetes: A clinical classification toolJacob V Stidsen, Jan E Henriksen, Michael H Olsen, et al.
Pageof 1